3/11
Remarkable back-to-back! #HeartFailure2025 #LBCT by
Marianna Fontana.
Nex-z CRISPR gene editing based therapy in #ATTRCM. Main paper in @nejm.org www.nejm.org/doi/full/10....
New data by #ATTR type with consistent and durable TTR lowering
#CardioSky #MedSky #Cardiology
1/11
Muthu Vaduganathan helped us share insights from #HeartFailure2025. Here are some highlights:
#LBCT by Marianna Fontana
#HELIOSB Recently FDA approved Vutrisiran RNAi therapeutic reduces mortality through 42 months in #ATTRCM
#CardioSky #MedSky #Cardiology
Starting tomorrow ➡️ #HeartFailure2025 🎉🎉
What I am most looking forward to:
⭐️ Topnotch #LBCT sessions
⭐️ #HFAYoung track - not to miss sessions ‼️
⭐️ #HFA_ESC millionaire quiz - daily at the HFA stage 🏆
⭐️ Meeting old & new friends ✨
Will I see you there? 🙋♀️
@novitham.bsky.social @escardio.bsky.social
Exciting data for new LBBAP ICD lead which is preliminary 200/300 pts completed. Excellent DFTs IF the ICD coil is pushed enough into the RV! Congratulations to the authors. #EPeeps #CardioSky #LBCT
#FlashbackFriday back to #ACC25!
Dr. Raj Makkar interviewed by Cardiovascular Business on the data from his #LBCT presentation of the Align-AR trial.
cardiovascularbusiness.com/topics/clini...
#LBCT #EAPC #ESCPrev2025
@PatriciaPalau1 presented RCT examining #CardiacRehab in #HFpEF + Chronotropic incompetence
✨4 different arms: adding in HRT or LRT 🆚 Regular 🆚 home
✨supervised exercise training=⬆️ peak Vo2, HR & QOL
✨moderate to high intensity stretch training best
#cardiosky #CVPrev
So honoured to be invited to #EAPC #EScPrev2025 and cochairing the #LBCT was quite fun with the amazing caliber of work presented
#CVPrev #CardioSky
#LBCT at #ESCPrev2025 @EJPCEiC #INTERASPIRE
✨Cardiac rehab globally varies in referal (Go Poland!🇵🇱)
✨over all 34% referral & 57% attendance
@escardio.bsky.social
#LBCT #EAPC #ESCPrev2025
@escardio.bsky.social
Queen of Hearts study@ChahindaGhoss
✨retrospective comparison of onset of CVD risk factors in women w/ preeclampsia 🆚 controls
✨CVD risk factors appear earlier in those with preeclampsia except T2DM compared with controls
#cardioobstetrics #cardiosky
#LBCT #ESCPrev2025
✨BA did not help lower LDL beyond the other patients in the control
✨ safe but ineffective
#BEMPED study @escardio.bsky.social
#LBCT #ESCPrev2025
#BEMPED study presented examining if the addition of bempedoic acid to statin+ezetimide improved a lipid control in ACS patients: RCT
✨no significant difference in % that for LDL <55mg/dL
#CVprev
#FlashbackFriday to last week's #ACC25 #LBCT
Hear from @smidtheart.bsky.social @womensheart.bsky.social Dr. Noel Bairey Merz & #UFmedicine Dr. Eileen Handberg on the largest trial on #INOCA the #WARRIORtrial.
#CardioSky
medicaldigest.org/scientific-c...
#DECODECKD trial #ACC25 #LBCT
Assessing DAPA CVD effects in CKD using echo to understand the mechanism of benefit
🫀<1/3 female ❌
🫀LV mass ⬇️ significantly in Dapa arm 🆚 placebo after 6m
🫀no change in LVEF or proBNP or Troponin, UACR but ⬇️eGFR
@accintouch.bsky.social
#ACC25 #LBCT
Preop Tx with Digifab on Acute Renal Injury undergoing CABG in those at risk for AKI
📌 <1/4 female, mean Cr 1.0 eGFR was 77
📌non significant diff in eGFR change or Cr
📌incidence of AKI was less in digifab arm
❤️ Phase 2 trial shows ⤵️ AKI but need larger studies
#cardiosky #CVPrev
🚨 #LBCT Align-AR
Dr. Raj Makkar presented data on patients with aortic regurgitation treated with a transcatheter aortic valve.
#ACC25 #CardioSky
#ACC25 #LBCT 5 year #EVOLUT Trial
❤️Low risk patients with symptomatic AS: what are the 5y outcomes of Sx 🆚 TAVI
💔1/3 Female
💔 all-cause Mortality gap ⬇️ with time
💔 CV mortality ⬇️ for TAVI
💔more pacemaker with EVOLUT
💥EVOLUT IN LOW RISK PATIENTS SAFE ALTERNATIVE TO Sx
BHF #protecttavi
#ACC25 #LBCT
❓Does routine use of Sentinel in TAVI reduce stroke
💥PROTECT TAVI demonstrates NO difference in Tx vs Control group in Stroke rate: currently would not use this in routine clinical practice
@nejm.org
www.nejm.org/doi/full/10....
Intensive medical therapy did not significantly impact the rate of serious CV events at five years in women w/ suspected INOCA, according to findings from WARRIOR presented during a #LBCT session at #ACC25.
Learn more: bit.ly/44a7uYO #MedSky #CardioSky
#APICAT trial at #ACC25 #LBCT #cardioonc
🩸apixaban low 2.5 mg vs full dose 5mg in patients with cancer+VTE: primary endpoint recurrent VTE
🩸more than half female! 👏🏽👏🏽
🩸the low dose was significant for noninferiority for efficacy & ⤵️ bleed
🩸no increase in deaths
#ACC25 #STRIDE examined Semaglutide in PAD #LBCT
👟function impairment is common in PAD with limited Tx
👟93% completed trial, 1/3 women,~ BMI 28, functionally limited (0.1/mile)
👟Sema 💉🆚UC in T2DM+symptoms PAD: walking distance ⤴️ by 13% out to 1 year🤯💥
#AHA24
#CVPrev
#LBCT
🫀178 patients with ASCVD
🫀dosing below 🆚 Placebo
🫀⤵️ Lp(a) by >80% during 36 weeks of tx, no safety concerns
@AHAScience @JAMA_current
📎 jamanetwork.com/journals/jam...
Among patients with ischemic cardiomyopathy & VT an initial strategy of catheter ablation ⚡️led to a lower risk of a composite primary end-point event 🆚 antiarrhythmic drug therapy 💊
#AHA24 #VANISH2 #LBCT
📎 www.nejm.org/doi/full/10....
First evidence of in vivo CRISPR/cas9 gene editing in ATTR-CM where targeting TTR has ⤵️ disease progression
#AHA24 #LBCT
💥💥💥💥💥💥💥💥
Wow! This is such amazing work and imagine what can be done if we diagnose early and can stop or reduce progression
#CardioSky
#AHA24 #LBCT ATTR-CM presented by Dr. Fontana
🫀 ATTR-CM is a progressive and deadly disease
🫀does TTR ⤵️improve outcomes? CRISPR/Cas9 can do this by targeting the gRNA as done here
🫀 97% male,22% Black
💥 ALL patients had ⤵️ TTR (⤵️89%) and most stable or improved PA& QoL
#CardioSky
#LBCT #SUMMIT trial #AHA24
💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity
📎 @NEJM www.nejm.org/doi/full/10....
Welcome @ahascience.bsky.social to BlueSky! I just arrived in Chicago and looking forward to #AHA24, seeing colleagues & hearing about the latest in CV Medicine. #CardioSky. I will be co-moderating the late breaking clinical trial session #LBCT 8 on Monday, all about #lipids !
#HRS2024 #LBCT by Dr Jeffrey Healey ARTESIA subclinical AF substudy eliquis vs ASA my take-home message: Eliquis >>> aspirin if CHADS VASc >4
